标题
Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
作者
关键词
-
出版物
Frontiers in Oncology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-05-27
DOI
10.3389/fonc.2020.00760
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
- (2020) Marine Cordonnier et al. Journal of Extracellular Vesicles
- Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
- (2019) Yi-Long Wu et al. Journal of Thoracic Oncology
- Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome
- (2019) Federico Innocenti et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- (2019) A B Schrock et al. ANNALS OF ONCOLOGY
- Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis
- (2019) Yibo Fan et al. ANNALS OF SURGICAL ONCOLOGY
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
- (2019) Mauro Poggio et al. CELL
- Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database
- (2019) Gaurav Singal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of TLR4 with Alzheimer's disease risk and presymptomatic biomarkers of inflammation
- (2019) Justin Miron et al. Alzheimers & Dementia
- Exosomes
- (2019) D. Michiel Pegtel et al. Annual Review of Biochemistry
- Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
- (2019) Pengfei Zhao et al. Journal of Hematology & Oncology
- Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy
- (2019) Jennifer Crow et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients
- (2019) Chuling Li et al. Journal of Translational Medicine
- The role of exosomal PD-L1 in tumor progression and immunotherapy
- (2019) Feiting Xie et al. Molecular Cancer
- AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
- (2018) Rui Ma et al. BRITISH JOURNAL OF CANCER
- Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth
- (2018) Yi Yang et al. CELL RESEARCH
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
- (2018) Jong-Ho Cha et al. MOLECULAR CELL
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis
- (2017) Kyle S. McCommis et al. HEPATOLOGY
- Prior irradiation results in elevated programmed cell death protein 1 (PD-1) in T cells
- (2017) Deguan Li et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
- (2017) Katerina Ancevski Hunter et al. Molecular Diagnosis & Therapy
- Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells
- (2017) Mengqi Yang et al. Molecular Oncology
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
- (2017) Linda Tran et al. Cancer Immunology Research
- Biomarkers associated with checkpoint inhibitors
- (2016) G. Manson et al. ANNALS OF ONCOLOGY
- Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
- (2016) Takehito Shukuya et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
- (2016) Lauren Van Der Kraak et al. Journal for ImmunoTherapy of Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
- (2011) X. Frigola et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation